Skip to main content
EJNMMI Research
Figure 1 | EJNMMI Research

Figure 1

From: [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

Figure 1

Effects of RO5126766 on cellular determinants of the uptake and retention of [18 F]FDG: (a) COLO320DM (wild type); (b) HCT116 ( K-ras mutant) (c) COLO205 ( B-raf ) mutant) cells were treated with RO5126766 for the indicated time- and dosage range and FDG uptake was assessed * p <0.05; ** p <0.01; (d) Western blotting analysis of the GLUTs and hexokinase II levels in three cell lines, actin is a loading control; (e) GLUT1 expression in plasma-membrane and cytosol fractions of HCT116 ( K - ras ) cells, treated with RO5126766 (1.3 μM). Na+ , K+ -ATP ase and actin protein levels in the cell membrane and cytosolic fractions (respectively) served as the fractions purity and loading controls; (f) Western blotting analysis of the hexokinase II activity in three cell lines, treated for 24 hours with RO5126766, 1.3 μM. Actin is a loading control.

Back to article page